Erudio Healtherudio.com
Clinical trial · no report yet · Phase 1
NCT03089203 trial: what clinicians have said so far
CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer
- NCT03089203 ↗
- Active, not recruiting
- University of Pennsylvania
- Focused size, estimated: 1–150 verified statements once built
We haven't built an HCP commentary report on NCT03089203 (metastatic castration-resistant prostate cancer) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03089203 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X, typically up to 13 once built |
The trial
ClinicalTrials.gov- Official title
- Phase I Study of CART-PSMA-TGFβRDN Cells in Patients With Advanced Castrate Resistant Prostate Cancer
- Phase
- Phase 1
- Status
- Active, not recruiting
- Conditions
- Prostate Cancer
- Interventions
- CART-PSMA-TGFβRDN cells; Cyclophosphamide; Fludarabine
- Arms
- Cohort 1 · Experimental
- Cohort 2 · Experimental
- Cohort -3 · Experimental
- Cohort 4 · Experimental
- Cohort 3 · Experimental
- Enrollment
- 23
- Primary outcomes
- Occurrence of study related adverse events, laboratory toxicities and clinical events that are possibly, likely, or definitely related to study participation.
- Clinical feasibility is defined as the frequency of subjects enrolled on this protocol who do not receive CART-PSMA-TGFβRDN cells.
- Manufacturing feasibility is determined by the frequency of product release failures and the occurrence of dose failures (inability to meet target dose).
- Sponsor
- University of Pennsylvania
- Start
- Mar 8, 2017
- Primary completion
- Sep 8, 2038 (estimated)
- Results posted
- No
- Registry record
- NCT03089203 · updated Feb 23, 2026
Publications
linked from the registry- Narayan V, Barber-Rotenberg JS, Jung IY, Lacey SF, Rech AJ, Davis MM, Hwang WT, Lal P, Carpenter EL, Maude SL, Plesa G, Vapiwala N, Chew A, Moniak M, Sebro RA, Farwell MD, Marshall A, Gilmore J, Lledo L, Dengel K, Church SE, Hether TD, Xu J, Gohil M, Buckingham TH, Yee SS, Gonzalez VE, Kulikovskaya I, Chen F, Tian L, Tien K, Gladney W, Nobles CL, Raymond HE; Prostate Cancer Cellular Therapy Program Investigators; Hexner EO, Siegel DL, Bushman FD, June CH, Fraietta JA, Haas NB. PSMA-targeting TGFbeta-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat Med. 2022 Apr;28(4):724-734. doi: 10.1038/s41591-022-01726-1. Epub 2022 Mar 21. PubMed 35314843
- Kloss CC, Lee J, Zhang A, Chen F, Melenhorst JJ, Lacey SF, Maus MV, Fraietta JA, Zhao Y, June CH. Dominant-Negative TGF-beta Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation And Augments Prostate Cancer Eradication. Mol Ther. 2018 Jul 5;26(7):1855-1866. doi: 10.1016/j.ymthe.2018.05.003. Epub 2018 May 8. PubMed 29807781